Thursday 10 Oct

News

Novo Nordisk to boost insulin to Egypt


Novo Nordisk to boost insulin to Egypt

Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population, met with Anna Dora Rijelsen, Danish Ambassador, and a Novo Nordisk delegation to discuss enhancing pharmaceutical cooperation. The meeting took place at the Ministry of Health and Population headquarters in the New Administrative Capital.

At the meeting's outset, Dr. Abdel Ghaffar thanked the Ambassador and Novo Nordisk for their support in supplying insulin to Egyptian diabetes patients. He emphasized the Ministry's commitment to a strong partnership with Novo Nordisk, a global leader in medical products for millions worldwide, including those with diabetes, hemophilia, and growth hormone deficiencies.

Dr. Hossam Abdel Ghaffar, the Ministry of Health and Population's official spokesperson, outlined the meeting's key discussions: enhanced cooperation as the meeting explored ways to strengthen collaboration in scientific research, innovation, and clinical research; physician training as it addressed the need for training healthcare professionals on the latest diagnostic and therapeutic methods for chronic diseases; and diabetes and obesity management where the meeting focused on strategies to prevent, manage, and avoid complications related to diabetes and obesity.

The meeting discussed also expanded diabetes care as the ministry aims to establish more diabetes treatment centers and educate patients across Egypt through NovoCare centers; global health leadership as Egypt's recognition by the World Health Organization as a leader in non-communicable disease research was highlighted; and pharmaceutical industry development where he meeting discussed supporting the growth of Egypt's pharmaceutical industry and its role as a regional hub for Africa.

For her part, the Danish Ambassador praised the strong and fruitful partnership between Egypt and Novo Nordisk, and the company's commitment to meeting the needs of the Egyptian drug market and Egyptian patients with all pharmaceutical products, confirming the company's aspiration to export to Africa through Egypt.

Dr. Jayajovandan Thiagarajan, Novo Nordisk's Regional Director for Africa, the Middle East, and Commonwealth countries, affirmed Egypt's strategic partnership with the company. He emphasized Novo Nordisk's commitment to serving Egyptian diabetes and obesity patients and expanding collaborations in healthcare training and education. The company has trained nearly 2,000 doctors in managing these conditions and has also focused on patient education and awareness initiatives.